Biotech Startups

Wanda Fish develops cell-cultivated seafood, with a flagship cultivated toro bluefin tuna product grown using cell culture and biotechnology methods. The company targets the sustainable food market as an alternative to wild-caught and aquaculture fish.

3 investors

WeedOUT develops a biological herbicide using proprietary sterile weed pollen to control resistant weeds in agriculture. The technology prevents viable seed formation in target weed species, addressing herbicide resistance while integrating into existing weed management programs.

3 investors

Wenzel Spine is a medical technology company that develops and manufactures products for minimally invasive spine surgery, including stand-alone spine fusion devices. It serves surgeons and their patients across the healthcare system, operating in the spine/orthopaedics medical device industry.

3 investors

WhiteLab Genomics uses AI and computational methods to analyze biological data and accelerate genomic drug discovery and development. The company serves pharmaceutical and biotech organizations seeking to reduce timelines and de-risk the development of genomic medicines.

3 investors

Xella is a women's precision health platform that combines multi-omic diagnostic testing with personalized clinical care, analyzing biological data to detect signs of 130+ conditions that often go undiagnosed in women. It offers a membership including physician-reviewed results, personalized care plans, and support across fertility, reproductive, hormonal, metabolic, and longevity health, aimed at women in the U.S.

3 investors

Xeltis develops implantable vascular devices that transform into living tissue using Restorex supramolecular polymer technology. The company targets patients requiring hemodialysis vascular access or cardiovascular replacements.

3 investors

XGenomes develops DNA sequencing technology that combines novel biochemistry, hardware, and algorithms to sequence single molecules of DNA directly, without library preparation or a bioinformatics bottleneck. It aims to deliver complete, highly accurate genome sequencing at low consumable cost, offered first as a service and later via an instrument-and-consumables model.

3 investors

XN Health develops a medical device that uses phrenic nerve stimulation to prevent ventilator-induced lung injury in mechanically ventilated patients by inducing diaphragm contractions. The device is intended for healthcare providers managing patients requiring mechanical ventilation support.

3 investors

XOMA Royalty is a biotech royalty aggregator that acquires the economic rights to future milestone and royalty payments tied to partnered pre-commercial clinical candidates, providing sellers with non-dilutive, non-recourse funding. It serves biotech companies seeking capital to advance their internal drug candidates, holding a portfolio of 120+ assets.

3 investors

YPrime provides a clinical trial technology platform with patient engagement features (eConsent and eCOA) designed to accelerate trial timelines, improve data quality, and enhance participant experience for pharmaceutical companies, biotechs, and contract research organizations.

3 investors

Yali develops fermentation technology to produce sustainable fats and lipids for alternative dairy products like ice cream, butter, and milk, using fewer inputs than conventional sources.

3 investors

Yuva Biosciences develops and licenses Y100, a cosmetic active ingredient that enhances mitochondrial health to reduce visible signs of aging for use in skincare and haircare products.

3 investors

Zai Lab is a global biopharmaceutical company developing and commercializing therapies in oncology, immunology, neuroscience, and infectious disease, with operations in China and the United States. The company combines in-licensed assets with internal R&D capabilities and has eight marketed products in China.

3 investors

Zentraxa precision-engineers bespoke bio-peptides and biomaterials, including adhesives inspired by marine mollusc chemistry that perform in wet, dirty and submerged conditions. Its products serve industries such as advanced wound care, ostomy bag adhesives, optical/transparent adhesives, and personal care ingredients, integrating into existing manufacturing lines.

3 investors

Alpha Fusion is a Japanese biotechnology company developing targeted alpha therapy drugs based on Astatine-211 (211At) to treat cancer with reduced side effects to healthy tissue.

3 investors

Endo-Phyte develops agricultural practices using endophytic fungi (Dark Septate Endophytes) to improve crop yields and soil health. The company serves agricultural producers and focuses on sustainable, regenerative farming methods in the agtech sector.

3 investors

LiberoThera is a drug discovery company using cell-free membrane protein preparation technology and non-natural amino acid incorporation technology to develop antibody-based therapeutics, including antibodies targeting GPCRs such as anti-CCR8. It operates through research alliances and partnerships in the biopharmaceutical field.

3 investors

Luxna Biotech develops nucleic acid medicines (oligonucleotide/antisense therapeutics) based on bridged/crosslinked modified nucleic acid chemistry originally developed at Osaka University. The company's licensed modifications aim to bind target mRNA more strongly, improve efficacy, reduce liver toxicity risk, and potentially alter tissue delivery of nucleic acid drugs.

3 investors

XtalPi is an AI-driven materials discovery platform that combines computational chemistry, machine learning, and automated wet lab experimentation to accelerate research in pharmaceuticals, new materials, and clean energy. The company serves biotech, pharmaceutical, and materials science organizations globally.

3 investors

FerroptoCure is a drug development company targeting ferroptosis pathways for therapeutic applications. The company focuses on advancing pharmaceutical candidates through clinical development stages in Japan and internationally.

3 investors

Gaudi Clinical is a Japanese company in the clinical and cellular field. Based on the company outline page, it appears to operate in cellular or clinical biotech, though the page does not explicitly detail specific products or services.

3 investors

StemRIM is a biopharmaceutical company developing regenerative medicine therapies. It is listed on the Tokyo Stock Exchange Growth Market (ticker 4599).

3 investors

Enu Pharma (遠友ファーマ) is a biotech startup developing antibody drugs with high selectivity based on a glycopeptide-targeting method discovered at Hokkaido University. The company aims to create new drug targets and therapies for patients with various diseases.

3 investors

GLPharmTech (지엘팜텍) develops incrementally modified drugs, including pregabalin extended-release tablets for neuropathic pain such as diabetic peripheral neuropathy and postherpetic neuralgia. The company is a South Korean pharmaceutical firm producing prescription central nervous system medications.

2 investors